Literature DB >> 7509538

Immunogens of bovine viral diarrhea virus.

S R Bolin1.   

Abstract

Bovine viral diarrhea virus (BVDV) is a ubiquitous pathogen of cattle that induces economically important diseases affecting multiple organ systems. In the United States, over 150 biological products are licensed for control of BVDV. These products contain live or killed BVDV, and many products contain other viruses or bacteria. Potency tests for these vaccines are based on animal inoculation and serology. For live virus vaccines, titration of viral infectivity in cell culture is an accepted alternative to animal inoculation. The immunogens in a killed virus vaccine may be measured by enzyme linked immunoabsorbent assay. Immunogens of BVDV that stimulate a protective immune response have not been conclusively identified. Epitopes on a putative viral envelope glycoprotein, gp53, are involved in viral neutralization. Other viral glycoproteins, gp48 and gp25, are immunogenic but epitopes on these proteins do not stimulate production of antibodies that efficiently neutralize virus. Progress in developing meaningful in vitro assays for quantitation of BVDV immunogens awaits identification of viral proteins that stimulate a protective immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509538     DOI: 10.1016/0378-1135(93)90028-6

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  17 in total

1.  Expression of a 50 kDa putative receptor for bovine viral diarrhea virus in bovine fetal tissues.

Authors:  L Zheng; S Zhang; W Xue; S Kapil; H C Minocha
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

2.  Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay.

Authors:  R W Fulton; J T Saliki; L J Burge; J M d'Offay; S R Bolin; R K Maes; J C Baker; M L Frey
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

3.  Expression of bovine viral diarrhea virus glycoprotein E2 as a soluble secreted form in a Mammalian cell line.

Authors:  Gaetano Donofrio; Ezio Bottarelli; Cavirani Sandro; Cesidio Filippo Flammini
Journal:  Clin Vaccine Immunol       Date:  2006-06

4.  Antigenic variation among bovine viral diarrhea virus (BVDV) strains and the role of different cell fixation methods in immunoassays.

Authors:  S M Elahi; S Harpin; E Cornaglia; B Talbot; Y Elazhary
Journal:  Can J Vet Res       Date:  1997-01       Impact factor: 1.310

5.  A new (old) bovine viral diarrhea virus 2 subtype: BVDV-2e.

Authors:  Pablo Sebastian Britto de Oliveira; José Valter Joaquim Silva Júnior; Rudi Weiblen; Eduardo Furtado Flores
Journal:  Arch Virol       Date:  2022-09-14       Impact factor: 2.685

6.  Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses.

Authors:  Sylvia van Drunen Littel-van den Hurk; Zoe Lawman; Marlene Snider; Don Wilson; Jan V van den Hurk; Barry Ellefsen; Drew Hannaman
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

7.  Severe malformations in calves associated with bovine viral diarrhoea (BVD) virus infection in a dairy cattle herd.

Authors:  A I Al-Afaleq; E M E Abu-Elzein; M Al-Khalyfah
Journal:  Trop Anim Health Prod       Date:  2007-10       Impact factor: 1.559

8.  Endotoxin-free purification for the isolation of bovine viral diarrhoea virus E2 protein from insoluble inclusion body aggregates.

Authors:  Antonino S Cavallaro; Donna Mahony; Margaret Commins; Timothy J Mahony; Neena Mitter
Journal:  Microb Cell Fact       Date:  2011-07-26       Impact factor: 5.328

9.  A transgenic ginseng vaccine for bovine viral diarrhea.

Authors:  Yugang Gao; Xueliang Zhao; Chao Sun; Pu Zang; He Yang; Ran Li; Lianxue Zhang
Journal:  Virol J       Date:  2015-05-07       Impact factor: 4.099

10.  Establishment of a bovine herpesvirus 4 based vector expressing a secreted form of the bovine viral diarrhoea virus structural glycoprotein E2 for immunization purposes.

Authors:  Gaetano Donofrio; Chiara Sartori; Lara Ravanetti; Sandro Cavirani; Laurent Gillet; Alain Vanderplasschen; Simone Taddei; Cesidio Filippo Flammini
Journal:  BMC Biotechnol       Date:  2007-10-18       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.